Gilead Announces Breakthrough HDV Treatment Data in New England Journal of Medicine
A study published in the New England Journal of Medicine and presented at the European Association for the Study...
Jon Napitupulu
Reducing Reliance on Animal Models: Charles River’s Virtual Control Groups
Charles River Laboratories and Sanofi have partnered to explore the use of Virtual Control Groups (VCGs) in nonclinical toxicology....
Elemind Introduces Sleep Solution, Empowering Sleep Control
Elemind, a neurotech wellness company, has introduced a revolutionary headband that harnesses advanced neurotechnology to improve sleep quality. The...
Be Bio: FDA Grants New Designation for Novel Medicine – Hemophilia B Breakthrough
Be Biopharma (Be Bio) announced that the FDA has granted Orphan Drug Designation to BE-101, an engineered B Cell...
Breyanzi: Remarkable Outcomes in B-Cell Malignancies Revealed
Long-term follow-up data from the TRANSFORM trial reveals that Breyanzi, a chimeric antigen receptor T-cell (CAR T) therapy, continues...
Legend Biotech shares data on CARVYKTI® in the treatment of multiple myeloma
Legend Biotech Corporation, a leader in cell therapy, announced positive results from its Phase 2 CARTITUDE-2 Cohort D study,...
Merck’s Innovative Oncology Pipeline Poised to Revolutionize Cancer Treatment
Merck KGaA, a science and technology leader, is expanding its oncology pipeline with promising new treatments. The company plans...
Visugromab/Nivolumab Combo Triumphs in Advanced Cancer Battle
Positive Results from CatalYm’s GDFATHER Trial CatalYm’s “GDFATHER” Phase 1/2a trial has shown promising results for its lead candidate,...
Bristol Myers Squibb Unveils Remarkable Analyses on Opdivo’s Efficacy in Non-Small Cell Lung Cancer
Bristol Myers Squibb’s ongoing research in non-small cell lung cancer (NSCLC) has yielded promising results in various stages of...
Obsidian’s OBX-115 Data Unveiled at ASCO 2024: Safety, Efficacy, and Surprises
Obsidian Therapeutics presented updated data from the Phase 1 study of OBX-115, an engineered tumor-derived autologous T-cell immunotherapy, at...